Cytogen, a US oncology imaging company with two marketed products, is to acquire Advanced Magnetics, an MRI pharmaceuticals company. The new company will benefit from advantages in marketing, manufacture, finance and R&D development from the all-share deal, valued at approximately $60 million.
Cytogen will move production of its two imaging agents, ProtaScint, a prostate cancer imaging agent and OncoScint, for ovarian and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?